AVITA Medical to participate at the TD Cowen 46th Annual Health Care Conference
Rhea-AI Summary
AVITA Medical (NASDAQ: RCEL) said interim CEO Cary Vance and CFO David O’Toole will present at the TD Cowen 46th Annual Health Care Conference in Boston on Wednesday, March 4, 2026 at 8:10 a.m. PT / 11:10 a.m. ET.
A live and archived webcast will be available via the company’s Events & Presentations page at its investor website.
Positive
- None.
Negative
- None.
News Market Reaction – RCEL
On the day this news was published, RCEL gained 11.13%, reflecting a significant positive market reaction. Argus tracked a peak move of +18.6% during that session. Our momentum scanner triggered 39 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $18M to the company's valuation, bringing the market cap to $181M at that time. Trading volume was above average at 1.8x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
RCEL gained 9.36% while peers were mixed: ICAD (+3.48%), LNSR (+3.18%), PROF (+0.58%) versus RPID (-1.77%) and SERA (-3.46%). The move appears more stock-specific than sector-wide.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 13 | Investor webinar | Positive | +11.8% | Announcement of investor webinar to review Q4 and FY 2025 results. |
| Feb 12 | Earnings results | Neutral | -3.1% | Reported Q4 and FY 2025 revenue growth with ongoing net losses and 2026 guidance. |
| Jan 25 | Clinical data update | Positive | +2.0% | Presented 19 abstracts showing benefits from integrated wound-care technologies. |
| Jan 13 | Pre-conference update | Positive | -3.5% | Pre-J.P. Morgan update on 2025 revenue growth, new credit facility, and 2026 outlook. |
| Jan 05 | Board changes | Neutral | +0.0% | Appointment of a new non-executive director and retirement of long-serving chairman. |
Recent AVITA news often elicits modest but mixed price reactions, with clinical and investor events sometimes drawing stronger interest than earnings updates.
Over the past two months, AVITA has reported Q4/FY 2025 results, issued 2026 revenue guidance of $80–85M, and highlighted integrated RECELL, PermeaDerm, and Cohealyx data with shorter hospital stays of nearly 16 days in one study. Investor communications, such as the Feb 18, 2026 webinar briefing, have coincided with notable moves (e.g., +11.83%). The latest conference participation fits a pattern of active outreach following financial and clinical updates.
Market Pulse Summary
The stock surged +11.1% in the session following this news. A strong positive reaction aligns with recent history where communication-focused events, such as the planned investor webinar that preceded a 11.83% move, drew heightened interest. Participation in a high-profile healthcare conference can reinforce visibility after AVITA’s Q4/FY 2025 results and guidance of $80–85M. However, past earnings-related announcements have seen mixed follow-through, so investors have previously reacted inconsistently to fundamentally similar updates.
AI-generated analysis. Not financial advice.
VALENCIA, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced Cary Vance, Interim CEO, and David O’Toole, CFO, will be participating in the upcoming TD Cowen 46th Annual Health Care Conference in Boston, MA.
AVITA Medical management is scheduled to participate in a presentation and fireside chat on Wednesday, March 4, at 8:10 a.m. Pacific Time / 11:10 a.m. Eastern Time. A live and archived webcast of the presentation will be accessible under the Events & Presentations section of AVITA Medical's website at: https://ir.avitamedical.com/events-and-presentations.
About AVITA Medical, Inc.
AVITA Medical® is a leading therapeutic acute wound care company delivering transformative solutions. Our technologies are designed to optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of our platform is the RECELL®, approved by the FDA for the treatment of thermal burn and trauma wounds. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin™, offering an innovative solution for improved clinical outcomes at the point-of-care. In the U.S., AVITA Medical also holds the exclusive rights to manufacture, market, sell, and distribute PermeaDerm®, a biosynthetic wound matrix, and the exclusive rights to market, sell, and distribute Cohealyx™, an AVITA Medical-branded collagen-based dermal matrix.
In international markets, RECELL is approved to promote skin healing in a wide range of applications including thermal burn and trauma wounds. RECELL and RECELL GO® have received the CE mark in Europe; and RECELL is TGA-registered in Australia, and has PMDA approval in Japan.
To learn more, visit www.avitamedical.com.
Investor & Media Contact:
Ben Atkins
Phone +1-805 341 1571
investor@avitamedical.com | media@avitamedical.com
Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.
©2026 AVITA Medical. AVITA Medical®, Cohealyx®, RECELL®, RECELL GO®, and Spray-On SkinTM are trademarks of AVITA Medical. PermeaDerm® is a registered trademark owned by Stedical Scientific, Inc. All other trademarks are the properties of their respective owners.
FAQ
When will AVITA Medical (RCEL) present at the TD Cowen 46th Annual Health Care Conference?
How can investors watch the AVITA Medical (RCEL) presentation at TD Cowen on March 4, 2026?
Who from AVITA Medical (RCEL) will participate in the TD Cowen conference presentation on March 4?
What topics will AVITA Medical (RCEL) cover at the TD Cowen 46th Annual Health Care Conference?
Where is the TD Cowen 46th Annual Health Care Conference taking place for AVITA Medical's presentation?
Will AVITA Medical (RCEL) provide an archived replay of its March 4, 2026 TD Cowen presentation?
